Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Engelholm

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|January 22, 2004
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?B Gronlund, H H Hansen, C Høgdall, et al.
International Journal of Cancer|January 15, 1985
Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude miceN Brünner, M Spang-Thomsen, H Skovgaard Poulsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1990
Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III studyD Nielsen, P Dombernowsky, T Skovsgaard, et al.
Investigational New Drugs|January 1, 1994
Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16L N Petersen, P B Jensen, B S Sørensen, et al.
Breast Cancer Research and Treatment|January 1, 1993
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trialL E Stenbygaard, J Herrstedt, J F Thomsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cellsK R Svendsen, K Overgaard-Hansen, S Frederiksen, et al.
Gynecologic Oncology|December 6, 2000
The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancerX Deng, E V Høgdall, C K Høgdall, et al.
Gynecologic Oncology|December 7, 2007
Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective studyS Risum, C Høgdall, A Loft, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 1996
Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiationF Bach, J B Sørensen, L Adrian, et al.
Cytometry|June 15, 1995
Prognostic significance of DNA content in bladder cancer based on flow cytometric analysis of 249 transitional cell carcinomasL L Vindeløv, I J Christensen, S A Engelholm, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|January 22, 2004
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?B Gronlund, H H Hansen, C Høgdall, et al.
International Journal of Cancer|January 15, 1985
Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude miceN Brünner, M Spang-Thomsen, H Skovgaard Poulsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1990
Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III studyD Nielsen, P Dombernowsky, T Skovsgaard, et al.
Investigational New Drugs|January 1, 1994
Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16L N Petersen, P B Jensen, B S Sørensen, et al.
Breast Cancer Research and Treatment|January 1, 1993
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trialL E Stenbygaard, J Herrstedt, J F Thomsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cellsK R Svendsen, K Overgaard-Hansen, S Frederiksen, et al.
Gynecologic Oncology|December 6, 2000
The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancerX Deng, E V Høgdall, C K Høgdall, et al.
Gynecologic Oncology|December 7, 2007
Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective studyS Risum, C Høgdall, A Loft, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 1996
Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiationF Bach, J B Sørensen, L Adrian, et al.
Cytometry|June 15, 1995
Prognostic significance of DNA content in bladder cancer based on flow cytometric analysis of 249 transitional cell carcinomasL L Vindeløv, I J Christensen, S A Engelholm, et al.
Pageof 6